Abstract

Scope Phaseolus vulgaris L. is rich in alpha‐amylase inhibitor and has been used for reducing glycemia and calories absorption through preventing or delaying the digestion of complex carbohydrate. A randomized, double‐blinded, placebo‐controlled study was conducted on obese volunteers to evaluate the degree of significate weight loss by regular intake Phaseolus vulgaris cultivated from Southwestern region of China.MethodThe volunteers were divided into two groups, homogeneous for age, gender, and body weight. Phaseolus vulgaris extract or placebo was given 2,400 mg per day before each daily meal for 35 consecutive days. Each subject's body weight, fat mass, body mass index, blood biochemical parameters, skinfold fat thickness, and waist/hip circumferences were monitored and analyzed.Result and conclusionAs a result, the average amount of weight lost by the Phaseolus vulgaris extract group was 2.24 kg (average of 0.448 kg per week), compared with a 0.29 kg weight loss (average of 0.058 kg per week) in placebo group after 35 days. The differences between groups were significant (p < .01). The body mass index decreased by an average of 0.79, and the body fat decreased by 1.53% on average compared to baseline (p < .05). The thickness of subcutaneous fat was significantly reduced at the four measurement points, and the decrease of waist circumference and hip circumference was significant as well. No adverse or side effects were observed during the trial period. The results indicate that Phaseolus vulgaris extract can significantly induce weight loss in a short time period.

Highlights

  • The World Health Organization (WHO) estimated that more than 1.9 billion adults (39% of men and 40% of women) aged 18 years and older were overweight in 2016 and of these over 650 million adults (11% of men and 15% of women) were obese

  • After 35 consecutive days, the phaseolus vulgaris extract (PVE) group have a significant reduction in body weight, body fat mass, body fat percentage, overweight percentage, and body mass index (BMI) at the baseline and at the end of trial (p < .01), whereas there was no significant change in the placebo group

  • The weight of the subjects dropped by an average of 2.24 kg after intake of PVE, which has a greater effect on body weight than does the placebo

Read more

Summary

Introduction

The World Health Organization (WHO) estimated that more than 1.9 billion adults (39% of men and 40% of women) aged 18 years and older were overweight in 2016 and of these over 650 million adults (11% of men and 15% of women) were obese. The worldwide prevalence of obesity nearly tripled between 1975 and 2016. There are more people who are obese than underweight—this occurs. . | 1316 in every region except parts of sub-Saharan Africa and Asia (WHO: Obesity & Overweight, 2018). Overweight and obesity are related to more deaths worldwide than underweight. The overweight and obesity states increase the risk of hypertension, type 2 diabetes, arthritis, sleep apnea, dyslipidemia, cardiovascular diseases, various types of cancer, and premature death (van Dam & Seidell, 2007; Willett, Dietz, & Colditz, 1999). Food science researchers have investigated many plant-derived foods consumption for decreasing energy intake on both animal experiments and human studies, trying to offer a promising therapy to ameliorate obesity and its complication

Objectives
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call